Skye Bioscience, Inc. Deferred Tax Assets, Capital Loss Carryforwards
Skye Bioscience, Inc. (SKYE) had Deferred Tax Assets, Capital Loss Carryforwards of $9.35 million as of 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsCapitalLossCarryforwards · last filed 2026-03-10
- 2025-12-31: Deferred Tax Assets, Capital Loss Carryforwards $9.35M.
- 2024-12-31: Deferred Tax Assets, Capital Loss Carryforwards $14.99M.
- 2023-12-31: Deferred Tax Assets, Capital Loss Carryforwards $17.16M.
- 2022-12-31: Deferred Tax Assets, Capital Loss Carryforwards $8.82M.
| Period end | Deferred Tax Assets, Capital Loss Carryforwards |
|---|---|
| 2025-12-31 | $9.35M 10-K · filed 2026-03-10 |
| 2024-12-31 | $14.99M 10-K · filed 2026-03-10 |
| 2023-12-31 | $17.16M 10-K · filed 2025-03-20 |
| 2022-12-31 | $8.82M 10-K · filed 2024-03-22 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |